The effects of transfer factor in adjuvant diseases in rats

The improvement of the course of adjuvant arthritis by thymosin led us to use the transfer factor (biological active fraction of the homogenate of human tonsillar leukocytes) in this reported experiment. Transfer factor administered in the amount 200 micrograms (analogy of 10' leukocytes) 3 times a week was able to completely prevent the development of adjuvant arthritis. In the period of maximum development of adjuvant arthritis, symptoms were observed in control rats not treated with transfer factor (on day 21 after complete Freund adjuvants application) while in the transfer factor treated rats, swelling of the paws was not demonstrated and the mobility was the same as in that of the healthy ones. Signs of bone lesions were not present in these animals as well. Transfer factor has only a weak effect on interferon production in vivo.